SGMO•benzinga•
Sangamo Therapeutics Gains FDA Clearance For IND Application Of ST-503 To Treat Idiopathic Small Fiber Neuropathy, Aiming To Address Chronic Neuropathic Pain With Phase 1/2 Study Enrollment Set For Mid-2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga